Skip to main content

Market Overview

(:) Press Releases

Thursday, February 27, 2020

Jounce Therapeutics, Inc. to Host Earnings Call (Earnings, JNCE, News, Press Releases / Thu, 07:00am)

Wednesday, February 26, 2020

Jounce Therapeutics to Present at Upcoming Investor Conferences in March (JNCE, News, Press Releases / Wed, 09:00am)

Friday, February 21, 2020

Jounce Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on Thursday, February 27, 2020 (JNCE, News, Press Releases / Fri, 02:25pm)

Thursday, February 06, 2020

Jounce Therapeutics Presents New Vopratelimab Predictive Biomarker Data Supporting Use in the Upcoming SELECT Trial at the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium Annual Meeting and Announces Research Collaboration with NanoString Technologies (JNCE, NSTG, Press Releases / Thu, 09:00am)

Thursday, January 23, 2020

Jounce Therapeutics Appoints Robert Iannone, M.D., M.S.C.E., to its Board of Directors (JNCE, News, Management, Press Releases / Thu, 09:00am)

Thursday, January 09, 2020

Jounce Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference (JNCE, News, Press Releases / Thu, 09:00am)

Thursday, December 19, 2019

Jounce Therapeutics to Present New Data on a Potential Predictive Biomarker from the Vopratelimab ICONIC Trial at the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium Annual Meeting (JNCE, News, Press Releases, General / Thu, 04:00pm)

Thursday, November 07, 2019

Jounce Therapeutics Reports Third Quarter 2019 Financial Results (Earnings, JNCE, Press Releases / Thu, 07:30am)

Tuesday, November 05, 2019

Jounce Therapeutics to Present Safety and Preliminary Efficacy Data on JTX-4014 and a Trials in Progress Poster for the Vopratelimab EMERGE Study at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting (JNCE, News, Press Releases / Tue, 09:05am)

Thursday, October 31, 2019

Jounce Therapeutics to Announce Third Quarter 2019 Financial Results and Host Conference Call on Thursday, November 7, 2019 (JNCE, Press Releases / Thu, 08:00am)

Tuesday, October 01, 2019

Jounce Therapeutics to Present Two Posters from the JTX-4014 and Vopratelimab Programs at the Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting (JNCE, News, Press Releases / Tue, 06:01pm)

Tuesday, September 17, 2019

Jounce Therapeutics Names Jacquelyn Fahey Sandell as Chief Legal Officer and Corporate Secretary (JNCE, News, Management, Press Releases / Tue, 08:00am)

Wednesday, August 28, 2019

Jounce Therapeutics to Present at Upcoming Investor Conferences in September (JNCE, News, Press Releases / Wed, 08:00am)

Wednesday, August 07, 2019

Jounce Therapeutics Reports Second Quarter 2019 Financial Results (Earnings, JNCE, Press Releases / Wed, 06:30am)

Wednesday, July 31, 2019

Jounce Therapeutics to Announce Second Quarter 2019 Financial Results and Host Conference Call on Wednesday, August 7, 2019 (JNCE, News, Press Releases / Wed, 08:00am)

Tuesday, July 23, 2019

Jounce Therapeutics Announces Update on Strategic Collaboration with Celgene Corporation (CELG, JNCE, Press Releases, General / Tue, 04:00pm)

Tuesday, June 18, 2019

Jounce Therapeutics Initiates Phase 2 EMERGE Study of Vopratelimab in Combination with Ipilimumab in Patients with Non-Small Cell Lung Cancer or Urothelial Cancer (JNCE, Press Releases / Tue, 08:00am)

Tuesday, June 11, 2019

Jounce Therapeutics to Present at Upcoming Investor Conferences in June (JNCE, News, Press Releases / Tue, 08:00am)

Wednesday, May 08, 2019

Jounce Therapeutics Reports First Quarter 2019 Financial Results (Earnings, JNCE, Press Releases / Wed, 06:30am)

Wednesday, May 01, 2019

Jounce Therapeutics to Announce First Quarter 2019 Financial Results and Host Conference Call on Wednesday, May 8, 2019 (JNCE, News, Press Releases / Wed, 08:00am)

Wednesday, April 03, 2019

Tuesday, April 02, 2019

Jounce Therapeutics Reports Improved PFS and OS Associated with Vopratelimab (JTX-2011) Treatment Emergent Biomarker at the 2019 American Association for Cancer Research (AACR) Annual Meeting (JNCE, Health Care, Press Releases / Tue, 01:02pm)

Wednesday, March 06, 2019

Jounce Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results (Earnings, JNCE, Press Releases / Wed, 07:30am)

Monday, March 04, 2019

Jounce Therapeutics to Present at Cowen and Company 39th Annual Health Care Conference (JNCE, News, Press Releases / Mon, 09:00am)

Thursday, February 28, 2019

Jounce Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Wednesday, March 6, 2019 (JNCE, Press Releases / Thu, 09:00am)

Wednesday, February 27, 2019

Jounce Therapeutics to Present Data from its JTX-2011 and JTX-8064 Programs at the 2019 American Association for Cancer Research (AACR) Annual Meeting (JNCE, News, Health Care, Press Releases / Wed, 05:35pm)

Thursday, January 03, 2019

Jounce Therapeutics Completed Enrollment in First Cohort of Phase 1 Clinical Trial with its PD-1 Inhibitor, JTX-4014 (JNCE, Press Releases / Thu, 09:00am)

Wednesday, January 02, 2019

Jounce Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference (JNCE, Press Releases / Wed, 09:00am)

Wednesday, November 28, 2018

Report: Exploring Fundamental Drivers Behind Matrix Service, NantHealth, Earthstone Energy, Jounce Therapeutics, BeiGene, and Oxford Immunotec Global — New Horizons, Emerging Trends, and Upcoming Developments (BGNE, ESTE, JNCE, MTRX, NH, OXFD, Analyst Ratings, Press Releases / Wed, 10:00am)

Tuesday, November 13, 2018

Jounce Therapeutics Reports Third Quarter 2018 Financial Results (Earnings, JNCE, Press Releases / Tue, 07:30am)

Saturday, November 10, 2018

Jounce Therapeutics Presents Reverse Translational, Biomarker and Preclinical Data from ICOS Program at the Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting (JNCE, News, Press Releases / Sat, 01:20pm)

Tuesday, November 06, 2018

Jounce Therapeutics to Announce Third Quarter 2018 Financial Results and Host Conference Call on Tuesday, November 13, 2018 (JNCE, Press Releases / Tue, 09:00am)

Friday, November 02, 2018

Friday, October 19, 2018

New Research Coverage Highlights Himax Technologies, Corporacion America Airports S.A, Tecnoglass, Jounce Therapeutics, Hollysys Automation Technologies, and Obsidian Energy — Consolidated Revenues, Company Growth, and Expectations for 2018 (CAAP, HIMX, HOLI, JNCE, OBE, TGLS, Press Releases / Fri, 09:15am)

1	PLUG: Why This Analyst Thinks Plug Power Stock Deserves Elevated Valuation
2	FCEL, PLUG: So What's Up With Plug Power And FuelCell Getting Hammered Today?
3	$ETH, $BTC: Coinbase Headed To $600 — Why Analyst Sees Crypto Exch...
4	SNAP: Why Snapchat Could Have A Big Quarter
5	WFC, GME: Here's Why GameStop And Wells Fargo Are...
6	DIS: What Are The 5 Drivers That Could Affect...
7	PLTR, NVAX: What's Going On With Palan...

1	BSQR, KSPN: 12 Information Technology Stocks Moving In Friday's Intraday Session
2	JAGX, ARDX: 12 Health Care Stocks Moving In Friday's Intraday Session
3	STZ, CGC: If You Invested $1,000 In Canopy Growth Stock One Ye...
4	TBLT, BALY: 12 Consumer Discretionary Stocks Moving In...
5	RELI, EQOS: 11 Financials Stocks Moving In F...
6	KSU: Recap: Kansas City Southern Q...
7	CMG, SPG: 10 Biggest Price Targ...